UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/555,039	09/12/2006	Jun Akai	03702/0203547-US0	2316	
7278 DARBY & DA	7590 05/30/200 RBY P.C.	8	EXAMINER		
P.O. BOX 770	-	BERNHARDT, EMILY B			
Church Street Station New York, NY 10008-0770			ART UNIT	PAPER NUMBER	
			1624		
			MAIL DATE	DELIVERY MODE	
			05/30/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Occurrence	10/555,039	AKAI ET AL.				
Office Action Summary	Examiner	Art Unit				
	EMILY BERNHARDT	1624				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence ad	dress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on						
	-· action is non-final.					
<i>,</i> —						
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
·		3 3.3.2.2.3.				
Disposition of Claims						
4) Claim(s) <u>1-6</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) <u>1-6</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign	priority under 35 LLS C. 8 119(a)	-(d) or (f)				
a)⊠ All b)□ Some * c)□ None of:	priority ariable 50 5.5.5. § 115(a)	(4) 01 (1).				
1. Certified copies of the priority documents	s have been received					
2. Certified copies of the priority documents		on No				
3. Copies of the certified copies of the prior	• •	<u> </u>	Stage			
	•	u III tilis National	Siage			
	application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)						
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date Notice of Informal Patent Application						
B) ☑ Information Disclosure Statement(s) (PTO/SB/08) 5) ☑ Notice of Informal Patent Application Paper No(s)/Mail Date 10/27/05. 6) ☑ Other:						
L - · · · - / - / · · · · · · · · · · · ·	,					

Claims 1-6 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

- 1. Claims 1 vs 2 appear to be substantial duplicates since for each set of claims the only difference is the added X-ray data. The X-ray data is an inherent characteristic and thus would not fail to distinguish (i.e. further limit) the claim(s) reciting the X-ray data. Thus it is not seen how infringing one of the pair would not infringe the remaining claim.
- 2. Throughout the claims mention is made of "a crystal" which literally recites a single particle. Perhaps crystal form was really intended? See claims 1,2 and 6.
- 3. In claim 3 "spontaneous nucleus" is not an art-recognized term. It appears from a discussion of the invention in the specification that the intended term is "spontaneous nucleation" which is art-recognized.

The disclosure is objected to because of the following informalities:

Terms such as "nucleus" appear inappropriate. "Nucleation" appears to be the intended term. Applicants are requested to check for additional terms that may be the result of a translation error.

Appropriate correction is required.

Application/Control Number: 10/555,039 Page 3

Art Unit: 1624

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claim 6 is rejected under 35 U.S.C. 102(b) as being anticipated by Kakemi, cited in applicants' International Search Report. While a copy has been provided in the original Japanese language, the examiner has obtained an English translation which is provided herewith. As acknowledged by applicants in the specification forms I-III of free base of instant compound is produced in Kakemi by dissolution in acetonitrile of the free base identified herein as A. However applicants also state that the polymorphic form III is NOT directly obtained from form A but rather from the acetonitrile solvate of A based on their isolation of the solvate and characterization data. However given that Kakemi employs acetonitrile to ultimately crystallize final products out of solution (see p.7), it would be reasonable for one of ordinary skill in the art to infer that standard isolation procedures were followed which include drying of the product by heating and/or under reduced pressure. Applicants rely on conventional procedure

Application/Control Number: 10/555,039 Page 4

Art Unit: 1624

for the desolvation step (see specification p.7) which would include the same procedure used in routine isolation of precipitates. Note Integra Life Sciences v. Merck 50 USPQ2d 1846.

US'049 is being cited as it is the equivalent to JP'680 cited by the JP examiner.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Emily Bernhardt whose telephone number is 571-272-0664.

If attempts to reach the examiner by telephone are unsuccessful, the acting supervisor for AU 1624, James O. Wilson can be reached at 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Application/Control Number: 10/555,039 Page 5

Art Unit: 1624

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Emily Bernhardt/
Primary Examiner, Art Unit
1624

.

Application/Control Number: 10/555,039 Art Unit: 1624

Page 6